Abstract
Classic serotonergic hallucinogens or psychedelics produce an altered states of consciousness (ASC) that is characterized by profound alterations in sensory perception, mood, thought including the perception of reality, and the sense of self. Over the past years, there has been considerable progress in the search for invariant and common features of psychedelic states. In the first part of this review, we outline contemporary approaches to characterize the structure of ASCs by means of three primary etiology-independent dimensions including oceanic boundlessness, anxious ego-dissolution, and visionary restructuralization as well as by 11 lower-order factors, all of which can be reliably measured by the altered state of consciousness questionnaire (APZ-OAV). The second part sheds light on the dynamic nature of psychedelic experiences. Frequently, psychedelic subjects progress through different stages over time and levels of changes along a perception-hallucination continuum of increasing arousal and ego-dissolution. We then review in detail the acute effects of psychedelics on sensory perception, emotion, cognition, creativity, and time perception along with possible neural mechanisms underlying them. The next part of this review outlines the influence of non-pharmacological factors (predictors) on the acute psychedelic experience, such as demographics, genetics, personality, mood, and setting, and also discusses some long-term effects succeeding the acute experience. The last part presents some recent concepts and models attempting to understand different facets of psychedelic states of consciousness from a neuroscientific perspective.
Keywords
- Psilocybin
- Lysergic acid diethylamide (LSD)
- Hallucinogens
- Psychedelics
- Altered states of consciousness
- Serotonin
- Human
The original version of this chapter was revised: Revised manuscript has been processed. The erratum to this chapter is available at 10.1007/7854_2017_477
This is a preview of subscription content, access via your institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Amabile TM (1982) Social psychology of creativity: a consensual assessment technique. J Pers Soc Psychol 43:997–1013
Aronson H, Silverstein AB, Klee GD (1959) Influence of lysergic acid diethylamide (LSD-25) on subjective time. AMA Arch Gen Psychiatry 1:469–472
Austin JH (1998) Zen and the brain: toward an understanding of meditation and consciousness. The MIT Press, Cambridge
Austin JH (2006) Zen-brain reflections: reviewing recent developments in meditation and states of consciousness. MIT Press, Cambridge, Massachusetts
Benedetti F, Barbini B, Bernasconi A, Fulgosi MC, Colombo C, Dallaspezia S, Gavinelli C, Marino E, Pirovano A, Radaelli D, Smeraldi E (2008) Serotonin 5-HT2A receptor gene variants influence antidepressant response to repeated total sleep deprivation in bipolar depression. Prog Neuropsychopharmacol Biol Psychiatry 32:1863–1866
Berlin L, Guthrie T, Weider A, Goodell H, Wolff HG (1955) Studies in human cerebral function: the effects of mescaline and lysergic acid on cerebral processes pertinent to creative activity. J Nerv Ment Dis 122:487–491
Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa P, Strassman RJ (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 29:289–299
Brogaard B (2013) Serotonergic hyperactivity as a potential factor in developmental, acquired and drug-induced synesthesia. Front Hum Neurosci 7:657
Buckman J (1967) Theoretical aspects of L.S.D. therapy. Int J Soc Psychiatry 13:126–138
Caldwell DF, Domino EF (1967) Effect of LSD-25 in the rat on operant approach to a visual or auditory conditioned stimulus. Psychol Rep 20:199–205
Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R, Malizia AL, Murphy K, Hobden P, Evans J, Feilding A, Wise RG, Nutt DJ (2012a) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 109:2138–2143
Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, Hobden P, Sharp DJ, Evans J, Feilding A, Wise RG, Nutt DJ (2012b) Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Br J Psychiatry 200:238–244
Carhart-Harris RL, Leech R, Erritzoe D, Williams TM, Stone JM, Evans J, Sharp DJ, Feilding A, Wise RG, Nutt DJ (2013) Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophr Bull 39:1343–1351
Carhart-Harris RL, Leech R, Hellyer PJ, Shanahan M, Feilding A, Tagliazucchi E, Chialvo DR, Nutt D (2014) The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci 8:20
Carhart-Harris RL, Kaelen M, Whalley MG, Bolstridge M, Feilding A, Nutt DJ (2015) LSD enhances suggestibility in healthy volunteers. Psychopharmacology 232:785–794
Carter OL, Pettigrew JD, Burr DC, Alais D, Hasler F, Vollenweider FX (2004) Psilocybin impairs high-level but not low-level motion perception. NeuroReport 15:1947–1951
Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX (2005) Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci 17:1497–1508
Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX (2007) Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology 195:415–424
Dahlberg CC, Jaffe J (1979) The effects of LSD-25 and dextroamphetamine on the use of defensive language. J Clin Psychol 35:250–254
Díaz JL (2010) Sacred plants and visionary consciousness. Phenom Cogn Sci 9:159–170
Dittrich A (1985) Ätiologie-unabhängige Strukturen veränderter Wachbewusstseinszustände. Ferdinand Enke Verlag, Stuttgart
Dittrich A (1994) Psychological aspects of altered states of consciousness of the LSD type: measurements of their basic dimensions and prediction of individual differences. In: Pletscher A, Ladewig D (eds) 50 years of LSD. Current status and perspective of hallucinogens. Parthenon, New York
Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31(Suppl 2):80–84
Dittrich A, von Arx S, Staub S (1981) International study on altered states of consciousness (ISASC). Schweiz Z Psychol und Anw 40:189–200
Dittrich A, von Arx S, Staub S (1985) International study on altered states of consciousness (ISASC). Summary of the results. Germ J Psych 9:319–339
Dobkin De Rios M, Janiger O (2003) LSD, spirituality and the creative process. Park Street Press, Rochester, Vermont
Dunsmore MW, Kaplan HB (1997) Peer support, perceptions of adverse effects, and the hallucinogenic drug experience. Appl Behav Sci Rev 5:219–230
Fischer R (1967) The biological fabric of time. Ann N Y Acad Sci 138:440–488
Fischer R (1971) A cartography of the ecstatic and meditative states. Science 174:897–904
Fischer R, Kaelbling R (1966) Increase in taste acuity with sympathetic stimulation: the relation of a just-noticeable taste difference to systemic psychotropic drug dose. Recent Adv Biol Psychiatry 9:183–195
Fischer R, Landon GM (1972) On the arousal state-dependent recall of ‘subconscious’ experience: stateboundness. Br J Psychiatry 120:159–172
Fischer R, Mead EL (1966) Time contraction and psychomotor performance produced by “Psilocybin”. Nature 209:433–434
Fischer R, Rockey MA (1967) A heuristic model of creativity. Experientia 23:150–151
Fischer R, Scheib J (1971) Creative performance and the hallucinogenic drug-induced creative experience or one man's brain-damage is another’s creativity. Confin Psychiatr 14:174–202
Fischer R, Georgi F, Weber R (1951) Psychophysical correlations. VIII. Experimental tests in schizophrenia: lysergic acid diethylamide and mescaline. Schweiz Med Wochenschr 81:817–819; contd
Fischer R, Griffin F, Archer RC, Zinsmeister SC, Jastram PS (1965a) Weber ratio in gustatory chemoreception; an indicator of systemic (drug) reactivity. Nature 207:1049–1053
Fischer R, Knopp W, Griffin F (1965b) Taste sensitivity and the appearance of phenothiazine-tranquilizer induced extrapyramidal symptoms. Arzneimittelforschung 15:1379–1382
Fischer R, Marks PA, Hill RM, Rockey MA (1968) Personality structure as the main determinant of drug induced (model) psychoses. Nature 218:296–298
Fischer R, Hill RM, Warshay D (1969a) Effects of psychodysleptic drug psilocybin on visual perception. Changes in brightness preference. Experientia 25:166–169
Fischer R, Thatcher K, Kappeler T, Wisecup P (1969b) Unity and covariance of perception and behavior. Perceptual variability: a predictor of psychotomimetic drug-induced behavior. Arzneimittelforschung 19:1941–1945
Fischer R, Hill R, Thatcher K, Scheib J (1970) Psilocybin-induced contraction of nearby visual space. Agents Actions 1:190–197
Forman RKC (1990) The Problem of pure consciousness. Mysticism and philosophy. Oxford University Press, New York
Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202:513–520
Gasser P, Kirchner K, Passie T (2015) LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol 29:57–68
Geyer MA, Vollenweider FX (2008) Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci 29:445–453
Gouzoulis E, Thelen B, Schreckenberger M, Kovar KA, Spitzer M, Sass H (1997) Human experimental neurometabolic and neuropsychological studies with psilocybin, d-methamphetamine and 3,4-methylenedioxyethylamphetamine (MDE). 20th symposium of AGNP nuremberg, 8–11 Oct 97. Pharmacopsychiat 30:171
Gouzoulis-Mayfrank E, Habermeyer E, Hermle L, Steinmeyer AM, Kunert HJ, Sass H (1998a) Hallucinogenic drug induced states resemble acute endogenous psychoses: results of an empirical study. Eur Psychiatry 13:399–406
Gouzoulis-Mayfrank E, Thelen B, Maier S, Habermeyer E, Spitzer M, Sass H (1998b) Modulation of semantic priming effects by psilocybin, MDE (ecstasy), and d-methamphetamine. Neurol Psychiatry Brain Res 6:19–28
Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, Kovar KA, Hermle L, Bull U, Sass H (1999) Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 20:565–581
Gouzoulis-Mayfrank E, Thelen B, Maier S, Heekeren K, Kovar KA, Sass H, Spitzer M (2002) Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans. Neuropsychobiology 45:205–212
Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187:268–283; discussion 284-92
Griffiths R, Richards W, Johnson M, McCann U, Jesse R (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22:621–632
Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer GR (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68:71–78
Grof S (1975) Realms of the human unconscious. Observations from LSD research. The Viking Press, New York
Gwynne PH, Fischer R, Hill R (1969) Hypnotic induction of the interference of psilocybin with optically induced spatial distortion. Pharmakopsychiatrie 2:223–234
Hanks JB, Gonzalez-Maeso J (2013) Animal models of serotonergic psychedelics. ACS Chem Neurosci 4:33–42
Harman WW, McKim RH, Mogar RE, Fadiman J, Stolaroff MJ (1966) Psychedelic agents in creative problem-solving: a pilot study. Psychol Rep 19:211–227
Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology 172:145–156
Heimann H (1963) Observations on disturbed time perception in model psychosis. Schweiz Med Wochenschr 93:1703–1705
Heimann H (1994) Experience of time and space in model psychoses. In: Pletscher A, Ladewig D (eds) 50 years of LSD. Current status and perspectives of hallucinogens. The Parthenon Publishing Group, New York
Hemsley DR, Ward ES (1985) Individual differences in reaction to the abuse of LSD. Person Individ Diff 6:515–517
Hermle L, Spitzer M, Borchardt D, Gouzoulis E (1992) Beziehungen der Modell- bzw. Drogenpsychosen zu schizophrenen Erkrankungen. Fortschr Neurol Psychiatr 60:383–392
Hill RM, Fischer R, Warshay D (1969) Effects of excitatory and tranquilizing drugs on visual perception. Spatial distortion thresholds. Experientia 25:171–172
Hofmann A (1968) Psychotomimetic agents. In: Burger A (ed) Chemical constitution and pharmacodynamic actions. M. Dekker, New York
Hyde RW (1960) Psychological and social determinants of drug action. In: Sarwer-Foner GJ (ed) The dynamics of psychiatric drug therapy. Thomas, Springfield, IL
Johnson M, Richards W, Griffiths R (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22:603–620
Kaelen M, Roseman L, Kahan J, Santos-Ribeiro A, Orban C, Lorenz R, Barett FS, Bolstridge M, Williams T, Williams L, Wall MB, Feidling A, Muthukumaraswamy S, Nutt DJ, Carhart-Harris R (2016) LSD modulates music-induced imagery via changes in parahippocampal connectivity. Eur Neuropsychopharmacol 26:1099–1109
Kast EC, Collins VJ (1964) Study of lysergic acid diethylamide as an analgesic agent. Anesth Analg 43:285–291
Kenna JC, Sedman G (1964) The subjective experience of time during lysergic acid diethylamide (Lsd-25) intoxication. Psychopharmacologia 5:280–288
Klüver H (1966) Mescal and mechanisms of hallucinations. University of Chicago Press, Chicago
Knoll M, Kugler J, Hofer O, Lawder SD (1963) Effects of chemical stimulation of electrically-induced phosphenes on their bandwidth, shape, number and intensity. Confin Neurol 23:201–226
Kometer M, Cahn BR, Andel D, Carter OL, Vollenweider FX (2011) The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biol Psychiatry 69:399–406
Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX (2012) Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry 72:898–906
Kometer M, Schmidt A, Jancke L, Vollenweider FX (2013) Activation of serotonin 2A receptors underlies the psilocybin-induced effects on alpha oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci 33:10544–10551
Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX (2014) Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry
Krippner S (1977) Research in creativity and psychedelic drugs. Int J Clin Exp Hypn 25:274–290
Krus DM, Wapner S, Freeman H, Casey TM (1963) Differential behavioral responsivity to LSD-25, study in normal and schizophrenic adults. Arch Gen Psychiatry 8:557–563
Krus DM, Resnick O, Raskin M (1966) Apparent eye level test. Its background and use in psychopharmacology. Arch Gen Psychiatry 14:419–428
Lamparter D, Dittrich A (1994) Differentielle Psychologie aussergewöhnlicher Bewusstseinszustände - Literaturübersicht und methodische Probleme. In: Dittrich A, Hofmann A, Leuner H (eds) Welten des Bewusstseins. Band 3. Experimentelle Psychologie, Neurobiologie und Chemie. VWB, Berlin
Leary T, Litwin GH, Metzner R (1963) Reactions to psilocybin administered in a supportive environment. J Nerv Ment Dis 137:561–573
Leuner H (1962) Die experimentelle psychose. Springer, Berlin/Göttingen/Heidelberg
Leuner H (1971) Halluzinogene in der Psychotherapie [Hallucinogens in psychotherapy]. Pharmacopsychiatry 4:333–351
Leuner H (1981) Halluzinogene. Psychische Grenzzustände in Forschung und Therapie. Hans Huber, Bern
Leuner H, Pletscher A, Ladewig D (1994) Hallucinogens as an aid in psychotherapy: basic principles and results. In: 50 years of LSD: current status and perspectives of hallucinogen research. The Parthenon Publishing Group, New York
Lienert GA, Netter P (1996) LSD response in Eysenckian trait types identified by polypredictive CFA. Personality Individ Differ 21:845–850
Ludwig AM (1966) Altered states of consciousness. Arch Gen Psychiatry 15:225–234
Maclean KA, Johnson MW, Griffiths RR (2010) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 25:1453–1461
MacLean KA, Leoutsakos JM, Johnson MW, Griffiths RR (2012) Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. J Sci Study Relig 51:721–737
Masters R, Houston J (2000) The varieties of psychedelic experience. Park Street Press, Rochester
McGlothlin W, Cohen S, McGlothlin MS (1967) Long lasting effects of LSD on normals. Arch Gen Psychiatry 17:521–532
Metzinger T (2009) The ego tunnel. The science of the mind and the myth of the self. Basic Books, New York
Metzner R, Litwin GH, Weil GM (1965) The relation of expectation and mood to psilocybin reactions: a questionnaire study. Psychedelic Rev 5:3–39
Moreau De Tours JJ (1973) Hashish and mental illness. Raven Press, New York
Moreno FA, Delgado PL (1997) Hallucinogen-induced relief of obsessions and compulsions. Am J Psychiatry 154:1037–1038
Muthukumaraswamy SD, Carhart-Harris RL, Moran RJ, Brookes MJ, Williams TM, Errtizoe D, Sessa B, Papadopoulos A, Bolstridge M, Singh KD, Feilding A, Friston KJ, Nutt DJ (2013) Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci 33:15171–15183
Natale M, Dahlberg CC, Jaffe J (1978) Effect of psychotomimetics (LSD and dextroamphetamine) on the use of primary- and secondary-process language. J Consult Clin Psychol 46:352–353
Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131–181
Nichols DE, Chemel BR (2006) The neuropharmacology of religious experience: hallucinogens and the experience of the divine. In: McNamara P (ed) Where God and science meet. Praeger, Westport, CT
Northoff G (2011) Self and brain: what is self-related processing? Trends Cogn Sci 15:186–187
Osmond H (1957) A review of the clinical effects of psychotomimetic agents. Ann N Y Acad Sci 66:418–434
Ott U, Reuter M, Hennig J, Vaitl D (2005) Evidence for a common biological basis of the Absorption trait, hallucinogen effects, and positive symptoms: epistasis between 5-HT2a and COMT polymorphisms. Am J Med Genet B Neuropsychiatr Genet 137B:29–32
Pahnke WN (1963) Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness. Harvard University Press, Cambridge
Passie T, Seifert J, Schneider U, Emrich HM (2002) The pharmacology of psilocybin. Addict Biol 7:357–364
Pekala RJ, Steinberg J, Kumar VK (1986) Measurement of phenomenological experience: pheneomenology of consciousness inventory. Percept Mot Skills 62:983–989
Quednow BB, Kuhn KU, Mossner R, Schwab SG, Schuhmacher A, Maier W, Wagner M (2008) Sensorimotor gating of schizophrenia patients is influenced by 5-HT2A receptor polymorphisms. Biol Psychiatry 64:434–437
Quednow BB, Schmechtig A, Ettinger U, Petrovsky N, Collier DA, Vollenweider FX, Wagner M, Kumari V (2009) Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: a replication study. Biol Psychiatry 66:614–620
Quednow BB, Kometer M, Geyer MA, Vollenweider FX (2012) Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology 37:630–640
Riba J, Rodriguez-Fornells A, Strassman RJ, Barbanoj MJ (2001) Psychometric assessment of the hallucinogen rating scale. Drug Alcohol Depend 62:215–223
Riba J, Romero S, Grasa E, Mena E, Carrio I, Barbanoj MJ (2006) Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant. Psychopharmacology
Sandison RA, Whitelaw JD (1957) Further studies in the therapeutic value of lysergic acid diethylamide in mental illness. J Ment Sci 103:332–343
Savage C, Fadiman J, Mogar R, Allen MH (1966) The effects of psychedelic (LSD) therapy on values, personality, and behavior. Int J Neuropsychiatry 2:241–254
Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Müller F, Borgwardt S, Liechti ME (2015) Acute effects of LSD in healthy subjects. Biol Psychiatry 78:544–553
Schmidt A, Bachmann R, Kometer M, Csomor PA, Stephan KE, Seifritz E, Vollenweider FX (2012) Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments. Neuropsychopharmacology 37:865–875
Schmidt A, Kometer M, Bachmann R, Seifritz E, Vollenweider F (2013) The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology 225:227–239
Schultes RE, Hofmann A (1980) The botany and chemistry of hallucinogens. Charles C. Thomas, Springfield
Serretti A, Drago A, de Ronchi D (2007) HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr Med Chem 14:2053–2069
Sessa B (2008) Is it time to revisit the role of psychedelic drugs in enhancing human creativity? J Psychopharmacol 22:821–827
Shanon B (2002) Ayahuasca visualizations. a structural typology. J Conscious Stud 9:3–30
Siegel RK (1977) Hallucinations. Sci Am 237:132–140
Siegel RK, Jarvik ME (1975) Drug-induced hallucinations in animals and man. In: Siegel RK, West LJ (eds) Hallucinations: behavior, experience and theory. Wiley, New York
Silverman J (1971) Research with psychedelics. Some biopsychological concepts and possible clinical applications. Arch Gen Psychiatry 25:498–510
Sinke C, Halpern JH, Zedler M, Neufeld J, Emrich HM, Passie T (2012) Genuine and drug-induced synesthesia: a comparison. Conscious Cogn 21:1419–1434
Hermle L, Fnfgeld M, Oepen G, Botsch H, Borchard D, Gouzoulis E, Fehrenbach RA, Spitzer, M (1993) Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry 32:976–991
Spitzer M, Braun U, Maier S, Hermle L, Maher BA (1993) Indirect semantic priming in schizophrenic patients. Schizophr Res 11:71–80
Spitzer M, Thimm M, Hermle L, Holzmann P, Kovar KA, Heimann H, Gouzoulis-Mayfrank E, Kischka U, Schneider F (1996) Increased activation of indirect semantic associations under psilocybin. Biol Psychiatry 39:1055–1057
Stace WT (1961) Mysticism and philosphy. Macmillan, London
Strassman RJ (2001) DMT: the spirit molecule. Park Street Press, Rochester, VT
Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Dose-response study of N, N-dimethyltryptamine in humans—II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51:98–108
Studerus E, Gamma A, Vollenweider FX (2010) Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One 5:e12412
Studerus E, Kometer M, Hasler F, Vollenweider FX (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25:1434–1452
Studerus E, Gamma A, Kometer M, Vollenweider FX (2012) Prediction of psilocybin response in healthy volunteers. PLoS One 7:e30800
Sysoeva OV, Tonevitsky AG, Wackermann J (2010) Genetic determinants of time perception mediated by the serotonergic system. PLoS One 5
Tagliazucchi E, Carhart-Harris R, Leech R, Nutt D, Chialvo DR (2014) Enhanced repertoire of brain dynamical states during the psychedelic experience. Hum Brain Mapp 35:5442–5456
ten Berge J (2002) Jekyll and Hyde revisited: paradoxes in the appreciation of drug experiences and their effects on creativity. J Psychoactive Drugs 34:249–262
Thatcher K, Wiederholt WC, Fischer R (1971) An electroencephalographic analysis of personality-dependent performance under psilocybin. Agents Actions 2:21–26
Tononi G (2004) An information integration theory of consciousness. BMC Neurosci 5:42
Umbricht D, Vollenweider FX, Schmid L, Grubel C, Skrabo A, Huber T, Koller R (2003) Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology 28:170–181
Unger SM (1963) Mescaline, LSD, psilocybin, and personality change. Psychiatry 26:111–125
Vollenweider FX (1998) Advances and pathophysiological models of hallucinogen drug actions in humans: a preamble to schizophrenia research. Pharmacopsychiat 31:92–103
Vollenweider FX (2008) Neurobiologie der Halluzinogenerfahrung. In: Jungaberle H, Gasser P, Weinhold J, Verres R (eds) Therapie mit psychoaktiven Substanzen. Verlag Hans Huber, Hogrefe AG, Göttingen
Vollenweider FX, Geyer MA (2001) A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 56:495–507
Vollenweider FX, Kometer M (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11:642–651
Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J (1997a) Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7:25–38
Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J (1997b) Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [F-18]-fluorodeoxyglocose (FDG). Eur Neuropsychopharmacol 7:9–24
Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997c) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16:357–372
Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Babler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9:3897–3902
Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB (2007) The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology 32:1876–1887
Wackermann J, Wittmann M, Hasler F, Vollenweider FX (2008) Effects of varied doses of psilocybin on time interval reproduction in human subjects. Neurosci Lett 435:51–55
Wapner S, Krus DM (1960) Effects of lysergic acid diethylamide, and differences between normals and schizophrenics on the stroop color-word test. J Neuropsychiatr 2:76–81
Weber K (1967) Alteration of music perception in experimental psychosis (psilocybin). Confin Psychiatr 10:139–176
Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider FX (2007) Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol 21:50–64
Zegans LS, Pollard JC, Brown D (1967) The effects of LSD-25 on creativity and tolerance to regression. Arch Gen Psychiatry 16:740–749
Acknowledgements
This article is dedicated to my dear friends—Dr. Dan Stoicescu and Dr. Bill Linton without whom much of this work would not have been possible (FXV).
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Preller, K.H., Vollenweider, F.X. (2016). Phenomenology, Structure, and Dynamic of Psychedelic States. In: Halberstadt, A.L., Vollenweider, F.X., Nichols, D.E. (eds) Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences, vol 36. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7854_2016_459
Download citation
DOI: https://doi.org/10.1007/7854_2016_459
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-55878-2
Online ISBN: 978-3-662-55880-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)